Race Oncology Appoints Associate Prof. Erin Howden to Scientific Advisory Board

Race Oncology (ASX: RAC) has appointed Associate Professor Erin Howden of the Baker Heart and Diabetes Institute to the company’s Scientific Advisory Board.

Dr. Howden is well-credentialed on the negative effects of chemotherapy on cardiorespiratory fitness and patient quality of life.

She is the Head of the Cardiometabolic Health and Exercise Physiology Lab and co-lead of the Physical Activity Program at the Baker Heart and Diabetes Institute

Recent work

Work by Dr. Howden and her collaborators has identified that VO2 peak is a highly sensitive and clinically relevant measure of the significant reductions in cardiorespiratory fitness experienced by cancer patients following exposure to anthracyclines.

The work found that anthracycline-containing treatments reduced average VO2 peak levels in cancer patients by 11%.

This is equivalent to 11 years of normal aging and with the rates of functional disability nearly doubling.

The Baker Heart and Diabetes Institute is an independent medical research facility.

The Institute’s work extends from the laboratory to wide-scale community studies with a focus on the diagnosis, prevention, and treatment of diabetes, cardiovascular disease, and associated metabolic diseases.

The appointment enhances Race’s cardioprotection-focused clinical program.

Dr Daniel Tillett, CEO, commented:

“It is no overstatement to say that Erin and her collaborators’ discoveries have provided Race with an incredible opportunity to accelerate our clinical program and bring our new formulation of bisantrene to patients sooner.”

Tillett added: “The importance of VO2 peak as a clinically relevant endpoint in cardiology is well established, but its use is highly innovative in oncology.”

Small molecule drug

Race’s drug Bisantrene, is a small molecule anthracene-based chemotherapeutic that has clinical data demonstrating anti-cancer and cardio-protection effects.

Originally developed in the 1970s and 1980s to create a less cardiotoxic, anthracycline-like chemotherapeutic, bisantrene has demonstrated efficacy and a well-characterized safety profile.

Bisantrene has been evaluated in more than 46 clinical trials, and 70 peer-reviewed publications, with over 1.8k patients treated.

Leveraging the drug’s rich clinical history, Race is now taking Bisantrene into two indications of unmet need: metastatic breast cancer and acute myeloid leukaemia (AML).



Articles of Interest